维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

16篇 您的检索式：作者名="Caulfield MP"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	The diagnosis of congenital adrenal hyperplasia in the newborn by gas chromatography/mass spectrometry analysis of random urine specimens显示文摘	Caulfield MP Lynn T Gottschalk ME	2002	J Clin Endocrinol Metab2002，87，8：	1
	2	Ionmobility analysis of lipoprotein subfractions identifies threeindependent axes of cardiovascular risk显示文摘	Musunuru K Orho-Melander M Caulfield MP	2009	ArteriosclerThromb Vasc Biol2009，29，11：	1
	3	Lipoprotein(a)concen- trations,rosuvastatin therapy,and residual vascular risk;An analysis from the JUPITER trial(justification for the use of statins in preven- tion:An intervention trial evaluating rosuvastatin)显示文摘	Khera AV Everett BM Caulfield MP	2014	Circulation: An Official Journal of the American Heart Association2014，129，6：	1
	4	Removal of partial agonism from parathyroid hormone (pth) -related protein-( 7-34 ) nh2 by substitution of pth amino acids at positions 10 and 11显示文摘	Nutt RF Caulfield MP Levy JJ	1990	Endocrinology1990，127，1：	1
	5	Muscarinic receptors-characterization, coupling and function显示文摘	Caulfield MP	1993	Pharmacol Ther1993，58，3：	1
	6	Relationship a- mong 25-hydroxyvitamin D concentrations,insulin action, and cardiovascular disease risk in patients with essential hypertension 显示文摘	Abbasi F Feldman D Caulfield MP	2015	Am J Hypertens2015，28，2：	1
	7	Muscarinic receptors-characterization, coupling and function显示文摘	Caulfield MP		Pharmacol Ther0，58，3：	1
	8	Muscarinic receptors- characterization, coupling and function显示文摘	Caulfield MP	1993	Pharmacd Ther1993，58，3：	1
	9	Lipoprotein (a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUP1TER Trial显示文摘	Khera AV Everett BM Caulfield MP	2013	Circulation2013，，：	1
	10	Muscarinic M-current inhibition via G alphaq/11 and alpha-adrenoceptor inhibition of Ca2+ current via G alphao in rat sympathetic neurones显示文摘	Caulfield MP Jones S Vallis Y	1994	J Physiol1994，477，3：	1
	11	Muscarinic receptors characterization coupling and function显示文摘	Caulfield MP	1993	Parmacol Ther1993，58，3：	1
	12	Lipoprotein ( a ) concentrations, rosuvastatin therapy, and residual vascular risk : an analysis from the JUPITER Trim (Justification for the Use of Statins in Prevention : an Intervention Trial Evaluating Rosuvastatin) 显示文摘	Khera AV Everett BM Caulfield MP	2014	Circulation2014，129，：	1
	13	Response to letter regarding article, 'lipoprotein ( a ) concentrations, rosuvastatin therapy, and residual vascular risk:an analysis from the JUPI- TER trial (justification for the use of statins in prevention:an intervention trial evaluating msuvastatin)' 显示文摘	Khera AV Everett BM Caulfield MP	2014	Circulation2014，130，17：	1
	14	Lipoprotein (a) concentrations, rosuvastatin therapy, and residual vascular risk : an analysis from the JUPITER Trial (Justifi- cation for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) 显示文摘	Khera AV Everett BM Caulfield MP	2014	Circulation2014，129，：	1
	15	Inhibition of osteoclastic bone resorptionin vivo by echistatin,an arginyl-glycyl-aspartyl (RGD)-containing protein显示文摘	Fisher JE Caulfield MP Sato M	1993	Endocrinoligy,1993，132，：	1
	16	脂蛋白a浓度,瑞舒伐他汀治疗和心血管剩留风险的关系显示文摘脂蛋白a是与低密度脂蛋白胆固醇(10wdensitylipoproteincholesterol,LDL—C)类似的颗粒,是独立于其他已知危险因素的心血管疾病(cardiovasculardisease,CVD)的预测因子。他汀类药物可消除脂蛋白a升高所造成的相关风险,但是脂蛋白a是否是强效他汀类药物治疗后与低LDL—C相关的心血管剩留风险的决定因素尚不清楚。方法与结果:JUPITER试验中的9612名各种族受试者随机分为接受瑞舒伐他汀治疗组(他汀组,20mg/d)和安慰剂组,评估其基线和治疗期间脂蛋白a浓度,并与白人受试者(n=7746)资料相比较。	Khera AV Everett BM Caulfield MP Hantash FM Wohlgemuth J Ridker PM Mora S	2013	中华高血压杂志2013，21，12：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费